Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C28H29F5O3 |
Molecular Weight | 508.5201 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@@](O)(C(F)(F)C(F)(F)F)[C@@]1(C)C[C@H](C3=CC=C(C=C3)C(C)=O)C4=C5CCC(=O)C=C5CC[C@@]24[H]
InChI
InChIKey=VHZPUDNSVGRVMB-RXDLHWJPSA-N
InChI=1S/C28H29F5O3/c1-15(34)16-3-5-17(6-4-16)22-14-25(2)23(11-12-26(25,36)27(29,30)28(31,32)33)21-9-7-18-13-19(35)8-10-20(18)24(21)22/h3-6,13,21-23,36H,7-12,14H2,1-2H3/t21-,22+,23-,25-,26-/m0/s1
Molecular Formula | C28H29F5O3 |
Molecular Weight | 508.5201 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Lonaprisan is an orally bioavailable pentafluoroethyl derivative of a mifepristone-related steroid with antiprogestagenic activity. Lonaprisan is a pure, highly receptor-selective progesterone receptor (PR) antagonist (both PR isoforms PR-A and PR-B); binding of this agent to PRs inhibits PR activation and the associated proliferative effects. Lonaprisan showed limited efficacy as second-line endocrine therapy in postmenopausal women with PR-positive metastatic breast cancer. Lonaprisan had been in phase II clinical trials by Bayer for the treatment of breast cancer and dysmenorrhea. However, this research has been discontinued.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Reversible suppression of menstruation with progesterone antagonists in rhesus macaques. | 2001 Aug |
|
Antiprogestin-releasing intrauterine devices: a novel approach to endometrial contraception. | 2007 Jun |
|
Intrauterine release of progesterone antagonist ZK230211 is feasible and results in novel endometrial effects: a pilot study. | 2007 Sep |
|
Global gene expression profiling of progesterone receptor modulators in T47D cells provides a new classification system. | 2009 Jan |
|
Progesterone receptor agonists and antagonists as anticancer agents. | 2010 Jun |
|
In vitro characterization of ZK 230211--A type III progesterone receptor antagonist with enhanced antiproliferative properties. | 2010 Mar |
|
The antiprogestin Lonaprisan inhibits breast cancer cell proliferation by inducing p21 expression. | 2011 Feb 10 |
|
Progesterone reverts LPS-reduced FAAH activity in murine peripheral blood mononuclear cells by a receptor-mediated fashion. | 2013 Dec 5 |
|
Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer. | 2013 Oct |
|
Progesterone modulates the LPS-induced nitric oxide production by a progesterone-receptor independent mechanism. | 2015 Dec 15 |
|
Acute exposure to progesterone attenuates cardiac contraction by modifying myofilament calcium sensitivity in the female mouse heart. | 2017 Jan 1 |
|
Discovery of Vilaprisan (BAY 1002670): A Highly Potent and Selective Progesterone Receptor Modulator Optimized for Gynecologic Therapies. | 2018 Nov 6 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23788750
Once-daily 25 mg or 100 mg
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:14:04 UTC 2023
by
admin
on
Fri Dec 15 16:14:04 UTC 2023
|
Record UNII |
F5Z5EL4D26
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1891
Created by
admin on Fri Dec 15 16:14:04 UTC 2023 , Edited by admin on Fri Dec 15 16:14:04 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
211254-73-8
Created by
admin on Fri Dec 15 16:14:04 UTC 2023 , Edited by admin on Fri Dec 15 16:14:04 UTC 2023
|
PRIMARY | |||
|
C71532
Created by
admin on Fri Dec 15 16:14:04 UTC 2023 , Edited by admin on Fri Dec 15 16:14:04 UTC 2023
|
PRIMARY | |||
|
F5Z5EL4D26
Created by
admin on Fri Dec 15 16:14:04 UTC 2023 , Edited by admin on Fri Dec 15 16:14:04 UTC 2023
|
PRIMARY | |||
|
DTXSID60893551
Created by
admin on Fri Dec 15 16:14:04 UTC 2023 , Edited by admin on Fri Dec 15 16:14:04 UTC 2023
|
PRIMARY | |||
|
Lonaprisan
Created by
admin on Fri Dec 15 16:14:04 UTC 2023 , Edited by admin on Fri Dec 15 16:14:04 UTC 2023
|
PRIMARY | |||
|
CHEMBL146032
Created by
admin on Fri Dec 15 16:14:04 UTC 2023 , Edited by admin on Fri Dec 15 16:14:04 UTC 2023
|
PRIMARY | |||
|
SUB129005
Created by
admin on Fri Dec 15 16:14:04 UTC 2023 , Edited by admin on Fri Dec 15 16:14:04 UTC 2023
|
PRIMARY | |||
|
8470
Created by
admin on Fri Dec 15 16:14:04 UTC 2023 , Edited by admin on Fri Dec 15 16:14:04 UTC 2023
|
PRIMARY | |||
|
C419162
Created by
admin on Fri Dec 15 16:14:04 UTC 2023 , Edited by admin on Fri Dec 15 16:14:04 UTC 2023
|
PRIMARY | |||
|
100000155105
Created by
admin on Fri Dec 15 16:14:04 UTC 2023 , Edited by admin on Fri Dec 15 16:14:04 UTC 2023
|
PRIMARY | |||
|
UU-124
Created by
admin on Fri Dec 15 16:14:04 UTC 2023 , Edited by admin on Fri Dec 15 16:14:04 UTC 2023
|
PRIMARY | |||
|
6918548
Created by
admin on Fri Dec 15 16:14:04 UTC 2023 , Edited by admin on Fri Dec 15 16:14:04 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|